Coya Therapeutics Inc (COYA, Financial) reported an insider purchase filed with the SEC. According to the SEC Filing, David Snyder, Chief Financial Officer of the company, bought 1,800 shares on November 14, 2024. The transaction occurred at a price of $7.19 per share, totaling $12,942. Following this transaction, the insider now owns 8,800 shares of Coya Therapeutics Inc.
Coya Therapeutics Inc is engaged in the development of therapies aimed at modulating the immune system to treat neurodegenerative and age-related diseases. This insider buying event may signal a positive outlook from the insider on the company's current valuation and future prospects.
Over the past year, David Snyder has engaged in multiple transactions, purchasing a total of 1,800 shares and selling none. This latest acquisition follows a trend observed within the company, where there have been four insider buys and no insider sells over the same period.
Shares of Coya Therapeutics Inc were trading at $7.19 on the day of the transaction, giving the company a market cap of approximately $113.778 million. This valuation provides investors with a reference for the company's size and market position.
For more detailed valuation metrics such as GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, investors can visit the respective links.
This insider purchase might be of interest to current and potential investors as it reflects the insider's confidence in the company's future direction and potential growth.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
